IMRX Immuneering Corporation

NASDAQ
$5.06

Immuneering Corporation (IMRX) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.31 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +13.5% since its last earnings release on August 5, 2026.

Immuneering Missed Consensus Estimates
Wednesday, August 5, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 7:35 AM ET
Earnings Whisper
-
vs ($0.31)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Immuneering Corporation

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process.

Sector

Healthcare

Industry

Biotechnology